Systemic Therapies for Pediatric Alopecia Areata.

Pediatr Dermatol

Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA.

Published: March 2025

Alopecia areata (AA) is an autoimmune hair loss disorder that commonly affects children. While mild disease may improve spontaneously or with topical therapies, patients with more extensive involvement typically require systemic treatment. This narrative review examines the literature describing systemic therapies for pediatric AA. High-quality evidence is extremely limited, with the majority of evidence coming from case reports and series. Janus kinase inhibitors are the only class of medications with systematic data supporting their use. There are an increasing number of reports suggesting that oral minoxidil may be beneficial, especially as an adjunctive treatment. Some patients with AA and comorbid atopy may benefit from treatment with dupilumab. Systemic corticosteroids may provide initial improvement, but the risk for adverse effects precludes long-term use, and efficacy is often lost once discontinued. There is very little literature to support the use of traditional immunomodulatory medicines such as methotrexate, cyclosporine, and azathioprine.

Download full-text PDF

Source
http://dx.doi.org/10.1111/pde.15822DOI Listing

Publication Analysis

Top Keywords

systemic therapies
8
therapies pediatric
8
alopecia areata
8
systemic
4
pediatric alopecia
4
areata alopecia
4
areata autoimmune
4
autoimmune hair
4
hair loss
4
loss disorder
4

Similar Publications

Advancing Tumor Microenvironment Analysis: A Fluorescence Nanosystem for Caspase-1 Monitoring and Synergistic Therapy.

Anal Chem

March 2025

College of Chemistry, Jilin Province Research Center for Engineering and Technology of Spectral Analytical Instruments, Jilin University, Qianjin Street 2699, Changchun 130012, China.

The lack of precise, real-time analytical tools for monitoring tumor microenvironment changes during treatment hinders advancements in integrated diagnostic and therapeutic platforms. Traditional caspase-3 monitoring strategies are limited by their inability to address drug resistance and newly discovered apoptotic pathways, leading to reduced accuracy and practicality. To overcome these limitations, we developed a fluorescence-based "Trojan horse" nanosystem, PFpR@CM, featuring high-sensitivity Caspase-1 detection, tumor-targeted delivery, and photothermal therapy.

View Article and Find Full Text PDF

Periodontitis is a significant global public health issue associated with the onset and progression of various systemic diseases, thereby requiring additional research and clinical attention. Although ferroptosis and cuproptosis have emerged as significant areas of research in the medical field, their precise roles in the pathogenesis of periodontitis remain unclear. We aim to systematically summarize the current research on ferroptosis and cuproptosis in periodontal disease and investigate the roles of glutathione pathway and autophagy pathway in connecting ferroptosis and cuproptosis during periodontitis.

View Article and Find Full Text PDF

BLIMP-1-dependent differentiation of T follicular helper cells into Foxp3 T regulatory type 1 cells.

Front Immunol

March 2025

Institut D'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.

T-regulatory-type-1 (TR1) cells are a subset of interleukin-10-producing but Foxp3 Treg cells that arise in response to chronic antigenic stimulation. We have shown that systemic delivery of autoimmune disease-relevant peptide-major histocompatibility complex class II (pMHCII)-coated nanoparticles (pMHCII-NP) triggers the formation of large pools of disease-suppressing Foxp3 TR1 cells from cognate T-follicular helper (TFH) cell precursors. Here we show that, upon treatment withdrawal, these Foxp3 TR1 cells spontaneously differentiate into a novel immunoregulatory Foxp3 TR1 subset that inherits epigenetic and transcriptional hallmarks of their precursors, including clonotypic T-cell receptors, and is distinct from other Foxp3 Treg subsets.

View Article and Find Full Text PDF

In recent years, the rapid progress in oncology, immunology, and molecular biology has dramatically advanced cancer immunotherapy, particularly CAR-T cell therapy. This innovative approach involves engineering a patient's T cells to express receptors that specifically target tumor antigens, enhancing their ability to identify and eliminate cancer cells. However, the effectiveness of CAR-T therapy in solid tumors is often hampered by the challenging tumor microenvironment (TME).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!